Arbutus Biopharma Corporation (ABUS) Financial Statements (2023 and Earlier)

Company Profile

Business Address 701 VETERANS CIRCLE
WARMINSTER, PA 18974
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:19112391125126131181
Cash and cash equivalents1095232375423167
Short-term investments467159887210715
Other undisclosed cash, cash equivalents, and short-term investments360     
Receivables1112111
Other undisclosed current assets(31)323211
Total current assets:16112894129129133184
Noncurrent Assets
Operating lease, right-of-use asset22 
Property, plant and equipment679101273
Long-term investments and receivables36  22  10
Long-term investments36  22  10
Intangible assets, net (including goodwill)   6683124515
Goodwill   222424163
Intangible assets, net (excluding goodwill)   445999353
Restricted cash and investments    1313 
Other noncurrent assets000    
Other undisclosed noncurrent assets  3    
Total noncurrent assets:4491299108143528
TOTAL ASSETS:204137106228237276712
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1197911109
Accounts payable3323233
Accrued liabilities1111112
Other undisclosed accounts payable and accrued liabilities7545855
Restructuring reserve  01   
Deferred revenue and credits301
Other undisclosed current liabilities0110111
Total current liabilities:1110811151111
Noncurrent Liabilities
Long-term debt and lease obligation23  1212 
Long-term debt, excluding current maturities    1212 
Operating lease, liability23 
Liabilities, other than long-term debt53342850154
Deferred revenue and credits1 0
Deferred rent credit   1
Deferred tax liabilities, net 1741146
Business combination, contingent consideration, liability53331097
Other undisclosed noncurrent liabilities16202213   
Total noncurrent liabilities:242625164062154
Total liabilities:353533285573165
Stockholders' equity
Stockholders' equity attributable to parent, including:16910273200182203548
Preferred stock    49  
Common stock1,287986899879876867834
Additional paid in capital65615548433730
Accumulated other comprehensive loss(48)(48)(48)(48)(48)(50)(50)
Accumulated deficit(1,134)(1,046)(970)(805)(738)(651)(267)
Other undisclosed stockholders' equity attributable to parent 1491371261  
Total stockholders' equity:16910273200182203548
TOTAL LIABILITIES AND EQUITY:204137106228237276712

Income Statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1176611125
Revenue, net11125
Gross profit:1176611125
Operating expenses(85)(65)(150)(96)(122)(493)(127)
Operating loss:(74)(58)(144)(90)(111)(492)(102)
Nonoperating income (expense)(3)(6)(22)282225
Investment income, nonoperating01228211
Foreign currency transaction gain (loss), before tax0(0)0(1)2122
Interest and debt expense(3)(4)(2)(0)(0)  
Other undisclosed income from continuing operations before equity method investments, income taxes   00  
Loss from continuing operations before equity method investments, income taxes:(79)(68)(168)(61)(109)(489)(77)
Other undisclosed income from continuing operations before income taxes 42    
Loss from continuing operations before income taxes:(79)(64)(166)(61)(109)(489)(77)
Income tax benefit  1342410516
Net loss:(79)(64)(154)(57)(84)(384)(61)
Other undisclosed net income attributable to parent3      
Net loss attributable to parent:(76)(64)(154)(57)(84)(384)(61)
Preferred stock dividends and other adjustments(12)(12)(11)(10)(1)  
Net loss available to common stockholders, diluted:(88)(76)(165)(67)(85)(384)(61)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(79)(64)(154)(57)(84)(384)(61)
Other comprehensive income (loss)(0)0(0)0   
Comprehensive loss:(79)(64)(154)(57)(84)(384)(61)
Comprehensive income, net of tax, attributable to noncontrolling interest 0     
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3     (27)
Comprehensive loss, net of tax, attributable to parent:(76)(64)(154)(57)(84)(384)(89)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: